Santen Pharmaceutical Co., Ltd. (SNPHF)
| Market Cap | 3.25B |
| Revenue (ttm) | 1.92B |
| Net Income (ttm) | 174.88M |
| Shares Out | n/a |
| EPS (ttm) | 0.49 |
| PE Ratio | 18.57 |
| Forward PE | n/a |
| Dividend | 0.12 (1.12%) |
| Ex-Dividend Date | Sep 27, 2024 |
| Volume | 299 |
| Average Volume | 728 |
| Open | 10.53 |
| Previous Close | 11.15 |
| Day's Range | 10.53 - 10.53 |
| 52-Week Range | 8.73 - 12.64 |
| Beta | 0.10 |
| RSI | 48.59 |
| Earnings Date | May 13, 2025 |
About Santen Pharmaceutical
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2α derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in pha... [Read more]
News
Santen Pharmaceutical Co., Ltd. (SNPHY) Management on Q1 2022 Results - Earnings Call Transcript
Santen Pharmaceutical Co., Ltd. (OTCPK:SNPHY) Q1 2022 Earnings Conference Call August 4, 2022 3:30 AM ET Company Participants Peter Sallstig - Chief Medical Officer Conference Call Participants Peter ...